The Cognex Corporation (CGNX) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, providing a structured view of how this industrial machine vision issuer reports its financial and corporate information. Cognex is incorporated in Massachusetts and files under Commission File Number 001-34218, with its common stock listed on NASDAQ under the symbol CGNX.
Among the key documents available are Form 10-K annual reports and Form 10-Q quarterly reports, where Cognex discusses its machine vision business, risk factors, and financial statements. These filings are important for understanding trends in logistics and factory automation demand, as well as the company’s investment in AI-enabled vision products, as referenced in its public communications.
Investors will also find Form 8-K current reports that Cognex uses to announce material events. Recent 8-K filings include the release of quarterly financial results, dividend declarations, and an audit firm rotation in which the Audit Committee selected KPMG LLP as the independent registered public accounting firm for a future fiscal year, following Grant Thornton LLP. Such filings provide timely insight into corporate actions and governance decisions.
On this page, users can monitor real-time updates from EDGAR, including 8-Ks, 10-Qs, 10-Ks, and other forms that Cognex may file. Stock Titan’s tools offer AI-powered summaries that help explain the contents of lengthy filings, highlight key sections, and clarify technical language around accounting, risk disclosures, and strategic priorities. In addition, Form 4 insider transaction reports, when filed, can be accessed to review share transactions by Cognex officers, directors, or significant shareholders.
By using the CGNX filings page, investors and researchers can quickly move from raw SEC documents to clearer explanations of how Cognex presents its financial condition, machine vision strategy, and corporate developments in official filings.
Cognex Corp director Robert Willett exercised stock options and sold the resulting shares in a same-day transaction. On 02/13/2026 he exercised 2,148 non-qualified stock options at $39.44 per share, receiving 2,148 shares of common stock, then sold those 2,148 shares at an average price of $59.5011 per share under a Rule 10b5-1 trading plan. Following these transactions he reported no directly held common shares, while continuing to hold multiple option grants and restricted stock units, plus 15,804 common shares held indirectly through the Willett Parkhill Investment Trust, where he is trustee and beneficiary and disclaims beneficial ownership beyond his pecuniary interest.
Cognex Corporation announced that its Board of Directors has appointed Dr. Sami Atiya and Mr. Chris Donato as directors, effective March 2, 2026. Dr. Atiya’s term will run to the 2028 annual meeting, while Mr. Donato’s term will run to the 2026 annual meeting.
Dr. Atiya is expected to join the Nominating, Governance and Sustainability Committee, and Mr. Donato is expected to join the Compensation Committee. Each will receive a $50,000 annual cash retainer, plus $5,000 for Dr. Atiya’s committee role and $8,000 for Mr. Donato’s committee role, along with initial RSU grants valued at about $275,000 that vest after one year.
In connection with these appointments, former CEO Robert Willett and Dr. Dianne Parrotte will retire from the Board on March 2, 2026, continuing an ongoing refresh of Cognex’s board with independent directors who bring automation, AI, and enterprise sales expertise.
Cognex director Robert Willett reported exercising stock options and selling the resulting shares on 02/12/2026. He exercised options for 173,296 shares at $38.39 and 3,756 shares at $39.44, then sold all 177,052 shares of common stock at an average price of $58.3851 per share in open-market transactions.
The filing shows remaining direct holdings of multiple non-qualified stock options covering hundreds of thousands of shares with exercise prices from $33.04 to $90.5, plus 70,824 restricted stock units and 15,804 shares held indirectly by a trust where Willett is trustee and beneficiary. The stock option exercises were carried out under a pre-established Rule 10b5-1 trading plan.
Cognex Corp VP and PAO Laura A. MacDonald reported option exercises and share sales on 02/12/2026. She exercised 12,500 non-qualified stock options at $38.39 per share, receiving an equal number of common shares.
MacDonald then made open-market sales totaling 14,881 common shares: 2,381 shares at $56.56 and 12,500 shares at $57.2707, pursuant to Rule 10b5-1 trading plans. After these transactions, she directly owned 2,212 common shares, plus various option and restricted stock unit awards, and 20 shares were held indirectly by her child with beneficial ownership disclaimed except for any pecuniary interest.
Cognex Corporation insider plans a new stock sale. A person for whose account the securities are to be sold filed to sell 2,148 shares of Cognex common stock on NASDAQ through Fidelity Brokerage Services, with an aggregate market value of $127,808.48.
The shares were acquired on 02/13/2026 via an option granted on 02/20/2024, paid in cash. Over the prior three months, Robert J. Willett sold 177,052 Cognex common shares for gross proceeds of $10,300,974.15, indicating substantial recent selling activity.
An affiliate of Cognex (CGNX) filed a notice of proposed resale of Cognex common stock under Rule 144. The notice covers planned sales of 2,381 shares and 12,500 shares through Robert W. Baird & Co., with aggregate market values of $134,670.00 and $715,884.00 on the NASDAQ. Cognex had 165,707,920 shares outstanding at the time referenced. The securities to be sold were acquired primarily through RSU releases in 2024 and 2025 and the cash exercise of a stock option originally granted in 2017.
Cognex Corporation shareholder files notice to sell restricted stock. A holder of Cognex common shares filed a Form 144 indicating an intention to sell 177,052 common shares through Fidelity Brokerage Services on NASDAQ, with an aggregate market value of $10,300,974.15 and 165,707,920 shares outstanding.
The shares relate to options granted on February 21, 2017 and February 20, 2024, which were acquired and paid in cash on February 12, 2026. Form 144 is a required notice before certain affiliates or large holders sell restricted or control securities.
Cognex Corporation files its 10-K describing how it uses machine vision and AI to automate manufacturing and logistics across logistics, packaging, consumer electronics, and automotive, which together were about 85% of 2025 revenue. Roughly 67% of sales came from customers outside the United States.
The company emphasizes AI‑driven products, a major salesforce transformation to double its customer base within five years, and selective acquisitions such as Moritex (enterprise value about $270 million). Research, development, and engineering spending was approximately $139 million, or 14% of revenue, in 2025.
Cognex returned cash through dividends and buybacks, paying $54.6 million of dividends in 2025 and repurchasing 4.234 million shares for $151.2 million, with $115.0 million remaining under its 2022 program and a new $500 million authorization. It ended 2025 with about $642 million in cash and investments and no long‑term debt.
Cognex Corporation reported a strong finish to 2025 and increased capital returns to shareholders. For the fourth quarter, revenue rose to $252 million, up 10% year over year, with operating margin at 14.0% and adjusted EBITDA margin at 22.7%. Adjusted diluted EPS grew 35% to $0.27.
For full-year 2025, revenue reached $994 million, up 9%, while adjusted diluted EPS increased 38% to $1.02. Adjusted EBITDA margin improved to 21.5%, or 20.7% excluding a one-time Commercial Partnership benefit. Cognex ended the year with $642 million in cash and investments and no debt, generated free cash flow of $237 million, and returned $206 million to shareholders.
The board declared a quarterly dividend of $0.085 per share, payable on March 12, 2026, and authorized an additional $500 million share repurchase capacity, supplementing the $115 million remaining as of December 31, 2025. First‑quarter 2026 guidance calls for revenue of $235–$255 million and adjusted diluted EPS of $0.22–$0.26, both above prior-year levels.
Cognex director Anthony Sun reported an indirect option exercise through Sun Management Associates, LLC. On January 8, 2026, the LLC exercised a non-qualified stock option for 26,000 shares of Cognex common stock at an exercise price of $16.72 per share, increasing its indirect common stock holdings to 52,608 shares. Separately from the LLC holdings, Sun is shown with 323,848 shares of common stock held directly, along with direct holdings of restricted stock units covering 8,324 and 2,913 shares. Following the exercise, the specific option grant for 26,000 shares is reduced to zero, while the LLC continues to hold additional non-qualified stock options for 26,000, 23,000, 26,000, and 13,000 shares at higher exercise prices. The filing notes that Sun is a member of the LLC and disclaims beneficial ownership of the LLC-held securities except to the extent of his pecuniary interest.